Is GlucoTrack, Inc. (GCTK) a Buy, Sell, or Hold?
GlucoTrack, Inc.
NASDAQ:GCTK
$0.5291 USD
$0.07 (14.13%)
- Volume
- 39.17M
- Average Volume
- 4.71M
- Market Capitalization
- $300.24K
- P/E Ratio
- -0.08
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $14.14
- Year Low
- $0.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.85
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Paul V. Goode |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | GCTK |
| CUSIP | 45824Q804 |
| CIK | 0001506983 |
| Web | https://www.glucotrack.com |
| Phone | 972 8 675 7878 |
| Currency | USD |
| Employees | 15 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.85 |
| Quick Ratio | 0.85 |
| Cash Ratio | 0.79 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -10.03 |
| Price / Cash Flow | -0.02 |
| Price / Book | -1.02 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-21.56 |
| Trailing P/E Ratio | -0.08 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-19.39M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -581.98% |
| Return on Assets | -387.72% |
Financials Score
| AltmanZ Score | -63.27 |
| Piotroski Score | 2.00 |
| Working Capital | -761K |
| Total Assets | 4.36M |
| Ebit | -17.03M |
| Market Cap | 263.07K |
| Total Liabilities | 5.21M |
Poll Results
About GlucoTrack, Inc. (NASDAQ:GCTK) Stock
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021. ...
2026-07-14 17:40:00
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
2026-07-08 08:00:00
RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.
2026-05-26 08:00:00
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association's (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-14 17:27:00
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology
2026-05-07 13:00:00
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform
2026-04-30 09:00:00
RUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company's fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model.
2026-04-21 08:00:00
RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company's fully implantable continuous blood glucose monitoring (CBGM) system.
Frequently Asked Questions
-
What is the current GlucoTrack, Inc. (GCTK) stock price?
-
GlucoTrack, Inc.(NASDAQ:GCTK) stock price is $0.5291 in the last trading session. During the trading session, GCTK stock reached the peak price of $14.14 while $0.291 was the lowest point it dropped to. The percentage change in GCTK stock occurred in the recent session was 14.13% while the dollar amount for the price change in GCTK stock was $0.07.
-
GCTK's industry and sector of operation?
-
The NASDAQ listed GCTK is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of GCTK?
-
Paul V. Goode | Chief Executive Officer, President & Director
David Malka | Co-Founder
Vincent Wong | Chief Operations Officer
Avner Gal MSc.EE | Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board
Mark Tapsak | Chief Scientific Officer -
How many employees does GCTK have?
-
Number of GCTK employees currently stands at 15. GCTK operates from 301 Route 17 North, Rutherford, None 7760049, US.
-
Link for GCTK official website?
-
Official Website of GCTK is: https://www.glucotrack.com
-
How do I contact GCTK?
-
GCTK could be contacted at phone #972 8 675 7878 and can also be accessed through its website. GCTK operates from 301 Route 17 North, Rutherford, None 7760049, US.
-
How many shares of GCTK are traded daily?
-
The average number of GCTK shares traded daily for last 3 months was 4.71M.
-
What is the market cap of GCTK currently?
-
The market value of GCTK currently stands at $300.24K with its latest stock price at $0.5291